BioWorld

June 4, 2008

Vertex Sells Royalty Rights to HIV Inhibitors for $160 Million

Vertex Pharmaceuticals Inc. is unloading two HIV protease inhibitors it helped develop in a $160 million deal with GlaxoSmithKline plc in which it agreed to sell rights to future royalties for Lexiva and Agenerase. (BioWorld Today) Read More

New Data Show Avant's Vaccine Doubles Survival in Brain Cancer

IRX Brings in $25M to Advance Lead Cancer Compound, IRX-2

NewCo News: NexBio Cuts Off Influenza Virus from its Entry Route

Gen-Probe Makes Counterbid for Diagnostics Firm Innogenetics

Other News To Note

ASCO Roundup: Incyte Slips on Myelofibrosis Data; ImmunoGen Falls, Too

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...